Lilly delves into social media for oncology art contest

Share this article:

Eli Lilly entered the Twittersphere without fanfare in early September for its fourth biennial Lilly Oncology on Canvas initiative, an art contest for those who have been affected by cancer.

Amy Sousa, a Lilly spokesperson, said the goals of the contest are the same, but the method for reaching participants has changed. “We're using social media tools…to engage participants,” she said, adding that anyone whom has experienced cancer – as a patient or caregiver – is eligible for the contest. Followers of Lilly's Twitter account will receive tweets about art exhibition dates, inspiring messages and other information, said Sousa. A Facebook page for the program is forthcoming.

The contest, which officially launches November 1, will run through June of 2010. Winners will be announced in fall of 2010, with the first prize receiving a $10,000 charitable donation to an organization of his or her choice.

Sousa said she is not aware of any immediate plans to launch new corporate Twitter accounts along the lines of several other large pharmaceutical companies, but said Lilly is “continuing to watch this space, particularly in light of the [DDMAC] hearing.”


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...